p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• p53-related protein kinase (TP53RK) phosphorylates and regulates p53 activity.
• TP53RK's role in multiple myeloma (MM) prognosis and therapeutic targeting remains largely unexplored.

Purpose of the Study:

• To investigate the prognostic significance of TP53RK in MM.
• To elucidate the mechanisms by which TP53RK influences MM cell survival and apoptosis.
• To evaluate TP53RK as a potential therapeutic target in MM.

Main Methods:

• TP53RK knockdown and its effects on MM cell apoptosis, p53 phosphorylation, and downstream targets (c-Myc, E2F-1, Bim).
• Identification of novel TP53RK downstream targets using molecular assays.
• Biochemical assays (pull-down, NMR, DSF, ITC) to assess the interaction between immunomodulatory drugs (IMiDs) and TP53RK.

Main Results:

• TP53RK expression correlates with poor prognosis in MM patients.
• TP53RK knockdown induces MM cell apoptosis, downregulates c-Myc, and upregulates Bim via E2F-1.
• TP53RK inhibition also affects p53-deficient/mutant MM cells, targeting novel pathways involving ribonucleotide reductase-1, telomerase reverse transcriptase, and CDK2C.
• IMiDs directly bind and inhibit TP53RK, mimicking the effects of TP53RK knockdown.

Conclusions:

• TP53RK is a key driver of poor prognosis in MM.
• Inhibition of TP53RK, either genetically or pharmacologically, induces MM cell apoptosis through both p53-dependent and independent mechanisms.
• TP53RK represents a promising therapeutic target for MM, particularly in patients with poor prognosis.